Walter, Eva <br/><br/>
Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.  [electronic resource] 

 -  Leukemia & lymphoma  Nov 2012 
 - 2290-2 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1029-2403 
<br/><br/><label>Standard No.: </label>10.3109/10428194.2012.682311  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antigens, CD20--analysis<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bendamustine Hydrochloride<br/>Cyclophosphamide--therapeutic use<br/>Doxorubicin--therapeutic use<br/>Female<br/>Humans<br/>Lymphoma, Large B-Cell, Diffuse--drug therapy<br/>Male<br/>Middle Aged<br/>Nitrogen Mustard Compounds--administration & dosage<br/>Prednisone--therapeutic use<br/>Retrospective Studies<br/>Rituximab<br/>Vincristine--therapeutic use